491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

Начало・Списък с акции・AB Science SA

AB Science SA

Затворен

1.184 0.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.164

Максимум

1.214

Ключови измерители
By Trading Economics
Приходи	-3.4M
Продажби	512K
Марж на печалбата	-656.641
Служители	28
EBITDA	-1.9M

Дивиденти
By Dow Jones
Следващи печалби	29.09.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	87M
Предишно отваряне	0.33
Предишно затваряне	1.184

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

1.426 / 1.448 Подкрепа & съпротива

AB Science SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2025 г., 23:59 ч. UTC

Придобивния, сливания и поглъщания

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8.09.2025 г., 22:02 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4 Billion AI Deal With Nebius

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Tron Shares Rise After New Investment From Bravemorning

8.09.2025 г., 16:14 ч. UTC

Значими двигатели на пазара

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8.09.2025 г., 16:13 ч. UTC

Значими двигатели на пазара

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8.09.2025 г., 22:56 ч. UTC

Пазарно говорене

Worst May Be Over for New Zealand Retailers -- Market Talk

8.09.2025 г., 22:23 ч. UTC

Пазарно говорене

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8.09.2025 г., 21:51 ч. UTC

Пазарно говорене

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8.09.2025 г., 21:47 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4B AI Deal With Nebius

8.09.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8.09.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8.09.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8.09.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 19:33 ч. UTC

Пазарно говорене

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8.09.2025 г., 19:22 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Higher -- Market Talk

8.09.2025 г., 19:02 ч. UTC

Пазарно говорене

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8.09.2025 г., 17:29 ч. UTC

Пазарно говорене

Mexican Inflation Seen Little Changed in August -- Market Talk

8.09.2025 г., 16:59 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8.09.2025 г., 16:36 ч. UTC

Пазарно говорене

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 16:16 ч. UTC

Печалби

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.09.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

AB Science SA Прогноза

Техническа оценка

By Trading Central

1.426 / 1.448Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.